1386 related articles for article (PubMed ID: 33897693)
1. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
2. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
4. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
Botticelli A; Cirillo A; Strigari L; Valentini F; Cerbelli B; Scagnoli S; Cerbelli E; Zizzari IG; Rocca CD; D'Amati G; Polimeni A; Nuti M; Merlano MC; Mezi S; Marchetti P
Front Immunol; 2021; 12():705096. PubMed ID: 34434192
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
[TBL] [Abstract][Full Text] [Related]
8. [Current events in immunotherapy for upper aerodigestive tract cancer].
Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
[TBL] [Abstract][Full Text] [Related]
9. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
10. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
11. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
[TBL] [Abstract][Full Text] [Related]
12. The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis.
Wang BC; Cao RB; Li PD; Fu C
Cancer Med; 2019 Oct; 8(13):5969-5978. PubMed ID: 31436392
[TBL] [Abstract][Full Text] [Related]
13. Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis.
Patel JJ; Levy DA; Nguyen SA; Knochelmann HM; Day TA
Head Neck; 2020 Apr; 42(4):774-786. PubMed ID: 31762164
[TBL] [Abstract][Full Text] [Related]
14. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
[TBL] [Abstract][Full Text] [Related]
16. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis.
Zhang S; Zheng M; Nie D; Xu L; Tian H; Wang M; Liu W; Feng Z; Han F
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253001
[TBL] [Abstract][Full Text] [Related]
18. The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments.
Outh-Gauer S; Morini A; Tartour E; Lépine C; Jung AC; Badoual C
Head Neck Pathol; 2020 Jun; 14(2):330-340. PubMed ID: 32124416
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis.
Galvis MM; Borges GA; Oliveira TB; Toledo IP; Castilho RM; Guerra ENS; Kowalski LP; Squarize CH
Crit Rev Oncol Hematol; 2020 Jun; 150():102966. PubMed ID: 32371338
[TBL] [Abstract][Full Text] [Related]
20. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]